42 results about "Respiratory epithelium" patented technology

The present invention is directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules.

An objective of the present invention is to provide a method of testing for bronchial asthma or chronic obstructive pulmonary disease, a method of screening for candidate compounds for treating bronchial asthma or chronic obstructive pulmonary disease, and a pharmaceutical agent for treating bronchial asthma or chronic obstructive pulmonary disease. The present invention identified genes whose expression levels varied between respiratory epithelial cells that had been stimulated by IL-13 to induce the goblet cell differentiation, and unstimulated respiratory epithelial cells. The respiratory epithelial cells were cultured according to the air interface method. The genes were revealed to be useful as markers for testing for bronchial asthma or chronic obstructive pulmonary disease and screening for therapeutic agents for such diseases. Specifically, the present invention provides methods of testing for bronchial asthma or chronic obstructive pulmonary disease and methods of screening for compounds to treat the diseases based on the comparison of the expression levels of marker genes identified as described above.

The invention is for a DNA vaccine expressing the hemagglutinin (HA1) gene of equine-2 influenza virus. By engineering a stop codon within HA1, expression of HA1 is ensured. By encapsulation of the DNA vaccine in liposome and by intranasal inoculation, it is sufficient to elicit protective immunity at a significantly lower dosage compared to a DNA vaccine expressing the full length HA gene. Lower dosage reduces the risk of induction of anti-DNA antibodies. Intranasal inoculation directly to the respiratory epithelial cells reduces the risk of DNA integration. The inventive vaccine is advantageous over current inactivated or live attenuated vaccines, as updating of the vaccine requires only the replacement of the encoding sequence with the new virus.

The present invention is directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules.

The invention relates to preservation of human local living parts and in particular relates to a culture medium for keeping primary airway epithelial cells in the physiological state in vivo during in vitro culture. The invention is characterized in that the culture medium contains the following components (per liter), 12 g of DMEM / F12 medium, 30 mg of penicillin G sodium salt, 50 mg of streptomycin, 10 mg of insulin, 5 mg of transferring, 25 Mug of epidermal growth factors, 100 Mug of cholera toxin, 108.741 Mug of hydrocortisone, 1 g of bovine pituitary extract, 3 g of bovine serum albumin, 1.5*10<-2> Mug of retinoic acid, 50 mg of gentamycin, 0.5 mg of amphotericin B, 50 mL of fetal calf serum and the balance of water. The primary airway epithelial cells cultured by the culture medium have the ciliary beating function and can maintain the physiological state in vivo.

The invention provides a scent bag for preventing cold and a preparing method thereof. The scent bag is composed of a scent bag body and medicine in the scent bag body. The medicine in the scent bag body is composed of radix sileris, herba eupatorii, wrinkled gianthyssop herb, mint, herba schizonepetae, rhizoma galangae, radix angelicae and clove. Medicinal materials are cut and then placed in an aroma bag, and finally the aroma bag is packaged in the scent bag body. Modern medicine research shows that traditional Chinese medicine with rich aromatic odor contains a large amount of volatile oil which has antibiosis and antiviral effects. Volatile oil in the scent bag can restrain adhesion of microorganisms on tracheal epithelium and slow down virus proliferation, has antibody activity for certain viruses, bacteria and ordinary antigen, and is the first defensive line for preventing pathogene from invading the body. By carrying the scent bag with someone, cold prevention and scent emission and odor elimination are achieved.

The invention discloses a siRNA (small interfering Ribose Nucleic Acid) of targeting genes ST6GAL1 and ST3GAL4 capable of preventing and controlling influenza. The siRNA comprises at least one of siST6GAL1_001, siST6GAL1_002, siST3GAL4_001, and siST3GAL4_002. The invention also provides a pharmaceutical composition of which the siRNA serves as an effective ingredient. The invention also provides an application of the siRNA in preparation of the pharmaceutical composition, a medicine and a prevention preparation for preventing and controlling influenza virus. By adopting the pharmaceutical composition, medicine and prevention preparation, the expression of a human influenza A virus sialic acid receptor and an avian influenza A virus sialic acid receptor on the surface of epithelial cell of human respiratory tract can be inhibited, thus the adsorption and infection of human and avian influenza A virus can be reduced effectively; in addition, the effective rate of the siRNA reaches more than 80% in the respiratory tract epithelial cell line.

The invention provides a construction method of an in-vitro respiratory exposure model, comprising the steps of inoculating respiratory epithelial cells to a porous membrane material on a co-culture system, culturing until the cells attach to a wall, wherein the membrane material divides the co-culture system into an upper chamber and a lower chamber; adding a cell culture medium into the lower chamber of the co-culture system, adding a lung surfactant to the upper chamber, and continuing to culture for 0.5-2 hours; adding a toxic material or a drug into the upper chamber to carry out exposure, and evaluating toxicological indexes of the respiratory epithelial cells. Application of the construction method of the in-vitro respiratory exposure model in environmental pollutant or drug evaluation is also provided.

The invention is related to findings that IL-17F-mediated inflammation of airway passages may be mediated via signaling through IL-17R on the basolateral surface of human respiratory epithelial cells. Thus, the present invention provides isolated and purified IL-17F or IL-17R polynucleotides and polypeptides. The present invention also is directed to novel methods for screening test compounds capable of inhibiting, i.e., decreasing, limiting, blocking, or otherwise reducing, IL-17F bioactivity, and methods for diagnosing, prognosing, and monitoring the progress of, disorders related to IL-17F bioactivity, e.g., disorders related to the effects of IL-17F binding to IL-17R on airway inflammation, e.g., in patients with cystic fibrosis, including pulmonary exacerbations due to bacterial infections in same. The present invention is further directed to novel therapeutics and therapeutic targets and to methods for the intervention (treatment) and prevention of said disorders related to IL-17F bioactivity.

The present invention relates to a method of treating respiratory epithelial lesions by topical or systemic administration of intestinal trilobite peptide. The intestinal trilopeptide may be administered alone or in combination with one or more therapeutic agents.

The present invention relates to the targeted delivery of a delivery vehicle construct which specifically binds to and stimulates endocytosis into cells expressing the urokinase plasminogen activator receptor (uPAR), and particularly human airway epithelia. The delivery vehicle construct comprises a portion of uPA and a cargo linked thereto and is useful for the targeted delivery of the cargo to a cell. In one aspect of the invention, the uPA portion of the delivery vehicle construct comprises the wild-type uPA, a fragment of uPA which has the PAI-1 binding region deleted, or a uPA peptide comprising amino acids 13-19 and is useful for the targeted delivery of the cargo to cells, and in particular to airway epithelia. The present invention also provides a method for delivering the delivery vehicle construct to a cell. The method comprises the steps of (a) contacting a target cell with a delivery vehicle construct comprising a uPA portion and a cargo portion; and (b) obtaining a desired result in the target cell.

The invention relates to a tool for in-vivo separating primary respiratory tract epithelial cells, and particularly relates to a two-material hollow casing pipe for separating primary respiratory tract epithelial cells. The two-material hollow casing pipe is characterized by being formed by bonding a silicone tube (small pipe diameter and high strength) and a Teflon hollow pipe (large pipe diameter, small strength and large flexibility) by virtue of silicone glue.

The invention provides an H7N9 avian influenza illness probability detection kit. The H7N9 avian influenza illness probability detection kit is characterized by comprising six pairs of PCR (Polymerase Chain Reaction) primers for detecting nine loci of five genes of CPT2-chr1: 53676448 & 53676401, CPT2-chr1: 53679229 & 53679028, FCGR2A-chr1: 161479745, IFITM3-chr11: 320772, RPAIN-chr17: 5326145 and TLR3-chr4: 187004074 & 187004217. The H7N9 avian influenza illness probability detection kit can find mutations at nine loci in total for an H7N9 patient and is applicable to detection for patients infected by H7N9 avian influenza and high-risk groups, thereby providing a certain value for prevention and control of H7N9 infection epidemic. Virulence genes identified by the H7N9 avian influenza illness probability detection kit may play a role in the pathogenesis of an H7N9 avian influenza infection process by entering epithelial cells in a respiratory tract in H7N9 infection and may also be susceptible genes of H7N9 avian influenza.

The invention discloses a quantitative detection method and a kit for rapid diagnosis of human respiratory pathogens. The kit is composed of: at least one human respiratory tract pathogen antibody capture microsphere, a PE-labeled detection antibody, a pathogen protein standard substance, a flow cytometry correction microsphere, a microsphere buffer solution, a cell lysis solution, a sample diluent and a cleaning solution; the kit is simple, convenient, rapid and automatic to operate, high in detection result sensitivity, wide in detection range and good in repeatability, quantitative detection of various pathogens in human respiratory tract epithelial cells and body fluid can be achieved, detection objects can be flexibly combined, and the infection condition of the pathogens can be reflected more truly.

The invention relates to a method for preventing and treating respiratory infectious diseases by using respiratory epithelial cell membranes and application. Specifically, the invention provides the use of respiratory epithelial cell membranes in the preparation of products for the prevention and / or treatment of respiratory infectious disease pathogen infection and corresponding products thereof, wherein the cell membranes may be unmodified or modified (e.g. modified to overexpress receptors on the surface of the cell membranes). The respiratory epithelial cell membranes and related products thereof can be widely applied to prevention and treatment of respiratory infectious disease pathogen infection, and the modified cell membranes can play a more effective role in prevention and treatment of specific pathogen infection.

The invention belongs to the field of biomedicine, and relates to establishment and application of a porcine respiratory tract epilhelium in-vitro 3D model. The porcine respiratory tract epilhelium in-vitro 3D model is a highly-differentiated nutrient material in a multilayer epithelium structure, which is obtained by carrying out in vitro culture on porcine respiratory tract epilhelia; and the top end surface of the nutrient material contains ciliated cells, mucous secretory cells and basal cells. The transepithelial electrical resistance is kept within the range of 250-350 ohm cm<2>. The cilia are distributed on the cell surface in clusters; abundant microvilli are visible on the cell surface; the diameter of the cilia is 0.3-0.5 mu m; and the length of the cilia is more than ten micrometers.

Three-dimensional human broncho-epithelial tissue-like assemblies (TLAs) are produced in a rotating wall vessel (RWV) with microcarriers by coculturing mesenchymal bronchial-tracheal cells (BTC) and bronchial epithelium cells (BEC). These TLAs display structural characteristics and express markers of in vivo respiratory epithelia. TLAs are useful for screening compounds active in lung tissues such as antiviral compounds, cystic fibrosis treatments, allergens, and cytotoxic compounds.

The invention is for a DNA vaccine expressing the hemagglutinin (HA1) gene of equine-2 influenza virus. By engineering a stop codon within HA1, expression of HA1 is ensured. By encapsulation of the DNA vaccine in liposome and by intranasal inoculation, it is sufficient to elicit protective immunity at a significantly lower dosage compared to a DNA vaccine expressing the full length HA gene. Lower dosage reduces the risk of induction of anti-DNA antibodies. Intranasal inoculation directly to the respiratory epithelial cells reduces the risk of DNA integration. The inventive vaccine is advantageous over current inactivated or live attenuated vaccines, as updating of the vaccine requires only the replacement of the encoding sequence with the new virus.

The invention relates to application of aerosol allicin to prevention and treatment of new coronavirus infection and other respiratory tract infectious diseases. The research finds that the new coronavirus only invades and infects respiratory tract epithelial cells expressing ACE2 and TMPRSS2; aerosol allicin can effectively inhibit TMPRSS2, so that new coronavirus is prevented from entering and infecting cells, infection factors in alveolar air can be eliminated, and new coronavirus infection can be effectively prevented and treated. In addition, the invention also finds that the aerosol allicin can effectively prevent and treat respiratory system diseases caused by infection factors of bacteria (such as mycobacterium tuberculosis, and Yersinia pestis), fungi (such as candida albicans andaspergillus niger), parasites (such as amoeba, giardia and leishmania), rickettsia and mycoplasma, and other viruses (such as influenza A, influenza B, encephalitis B, SARS, MERS, avian influenza and African swine fever) of non-SARSARS-CoV-2. Clinical application prospect is wide.

The invention is related to findings that IL-17F-mediated inflammation of airway passages may be mediated via signaling through IL-17R on the basolateral surface of human respiratory epithelial cells. Thus, the present invention provides isolated and purified IL-17F or IL-17R polynucleotides and polypeptides. The present invention also is directed to novel methods for screening test compounds capable of inhibiting, i.e., decreasing, limiting, blocking, or otherwise reducing, IL-17F bioactivity, and methods for diagnosing, prognosing, and monitoring the progress of, disorders related to IL-17F bioactivity, e.g., disorders related to the effects of IL-17F binding to IL-17R on airway inflammation, e.g., in patients with cystic fibrosis, including pulmonary exacerbations due to bacterial infections in same. The present invention is further directed to novel therapeutics and therapeutic targets and to methods for the intervention (treatment) and prevention of said disorders related to IL-17F bioactivity.

The invention provides application of a traditional Chinese medicine composition in preparation a medicament for treating upper airway cough syndrome. The traditional Chinese medicine composition is characterized by comprising, 5-15 parts of antelope horn or 50-150 parts of goat horn, 10-60 parts of fritillary bulb, 15-60 parts of rheum officinale, 7-30 parts of radix scutellariae, 7-30 parts of chlorite schist, 10-50 parts of gypsum, 5-20 parts of artificial bezoar, and 15-60 parts of licorice root. The compound combination medicine for treating upper airway cough syndrome can significantly inhibit the production of inflammatory factors of macrophage RAW 264.7 induced by LPS; and can significantly inhibit the secretion of mucin MUC5AC in respiratory epithelial cells stimulated by PolyI:C.In rats with upper airway cough syndrome, the traditional Chinese medicine composition can reduce an inflammatory state score of rats and reduce the levels of inflammatory factors IL-8 and TNF-a in serum.

This invention features methods of treating lesions of the airway epithelium by local or systemic administration of intestinal trefoil peptides. The intestinal trefoil peptide can be administered either alone or in combination with one or more therapeutic agents.

The invention discloses an antiviral oral spray and a preparation method thereof. The antiviral oral spray is prepared from the following components in parts by mass: 13 to 25 parts of honeysuckle flower, 13 to 25 parts of radix scutellariae, 13 to 25 parts of fructus forsythiae, 12 to 22 parts of folium isatidis, 6 to 11 parts of liquorice root, 5 to 10 parts of radix bupleuri, 5 to 10 parts of flos chrysanthemi indici, 5 to 10 parts of radix isatidis, 0.2 to 0.8 part of menthol, 5 to 10 parts of herba houttuyniae, 1.0 to 2.0 parts of sucralose, 0.25 to 0.85 part of 95% benzalkonium bromide, 400 to 600 parts of ethyl alcohol, and the balance purified water, wherein the total amount is 1000 parts. The antiviral oral spray has the advantages that the functions of killing and inhibiting viruses in oral cavity are realized, and the killing rate on staphylococcus aureus and pseudomonas aeruginosa reaches 99.999% within 5min; the average killing logarithmic time on candida albicans is longer than 4.00min, and the killing rate is also higher than 99.99%; and the oral inflammation and respiratory tract epithelial mucosa injury caused by virus replication can be prevented, the spreading of droplets with viruses is effectively prevented, and the function of preventing the spreading and diffusion of novel coronavirus is effectively realized.

The invention relates to the field of human respiratory tract epithelial cell pathogen detection, in particular to a human respiratory tract epithelial cell pathogen cytology detection method and a kit. The method comprises the following steps of: S1, sample acquisition: collecting human respiratory tract epithelial cells, and fixing the human respiratory tract epithelial cells in a cell preservation solution; S2, flaking: manually or automatically adding a sample onto a sample carrying medium; S3, incubating: incubating the sample by adopting an immune cell chemical staining technology and / ora chromogenic in-situ hybridization technology; and S4, positive sample judgment: manually counting and identifying positive cells and outputting a diagnosis report, or automatically counting and outputting an auxiliary diagnosis report after computer scanning. With the human respiratory tract epithelial cell pathogen cytology detection method and the kit adopted, the defects of an existing diagnosis means, such as nucleic acid loss in a sample extraction process in nucleic acid detection can be eliminated; and a virus detection rate can be improved. The method is more sensitive, specific andefficient than nucleic acid detection, CT and other serological detection products which are conventionally used at present and serological test products which are under development.

The invention belongs to the fields of tissue engineering and a medical material, relates to an airway epithelium-porous silk fibroin protein complex, and a preparation method and application thereof, and particularly relates to a method for carrying out airway epithelium cultivation on porous silk fibroin protein, and application of the airway epithelium-porous silk fibroin protein complex in trachea defect reconstruction. The porous silk fibroin is adopted as a bracket material; a primary human airway epithelium cell is taken as a seed cell; the airway epithelium cell is subjected to composite cultivation on the porous silk fibroin protein, so as to form the airway epithelium-porous silk fibroin protein complex. The complex is covered on the inner wall of an artificial trachea, so that the inner wall of the artificial trachea is covered by respiratory mucosa, so as to be closer to a normal trachea structure; the artificial trachea can be further applied to preparation of a tissue engineering trachea, repair of clinical tracheal mucosa and clinical tracheal defect reconstruction, and reduction of postoperative complications of tracheal reconstruction as the medical material.

The invention discloses a method for establishing an EBV (Epstein-Barr Virus) infected artificial respiratory tract epithelium model. The method comprises the following steps: (1) digesting nasopharyngeal mucosa tissues by using Dispase II, performing beating into single cells, and performing centrifuging to remove supernate, so as to obtain cell precipitate; (2) suspending and culturing the cellprecipitate by using an epithelial cell culture medium; (3) performing digesting into single cells, planting the single cells in a small chamber above the 24-hole support membrane, and performing culturing until the support membrane is overgrown; (4) completely removing the culture solution above the support membrane, and continuously culturing for 2-3 weeks; and (5) when large-area cilium swinging is observed, adding Akata cells to carry out cell contact mediated EBV infection, and when successful infection, obtaining the artificial respiratory tract epithelium model infected with the EBV. According to the establishing method, nasopharyngeal mucosa tissue is taken as a material part, nasopharyngeal epithelial cells can be differentiated into completely polarized pseudo-multilayer respiratory tract epithelial tissue through gas-liquid interface culture, and the nasopharyngeal epithelial tissue is completely simulated by basal layer cells, secretory cuppy cells and swinging cilium cells.

The invention discloses a siRNA (small interfering Ribose Nucleic Acid) of targeting genes ST6GAL1 and ST3GAL4 capable of preventing and controlling influenza. The siRNA comprises at least one of siST6GAL1_001, siST6GAL1_002, siST3GAL4_001, and siST3GAL4_002. The invention also provides a pharmaceutical composition of which the siRNA serves as an effective ingredient. The invention also provides an application of the siRNA in preparation of the pharmaceutical composition, a medicine and a prevention preparation for preventing and controlling influenza virus. By adopting the pharmaceutical composition, medicine and prevention preparation, the expression of a human influenza A virus sialic acid receptor and an avian influenza A virus sialic acid receptor on the surface of epithelial cell of human respiratory tract can be inhibited, thus the adsorption and infection of human and avian influenza A virus can be reduced effectively; in addition, the effective rate of the siRNA reaches more than 80% in the respiratory tract epithelial cell line.

This invention features methods of treating lesions of the airway epithelium by local or systemic administration of intestinal trefoil peptides. The intestinal trefoil peptide can be administered either alone or in combination with one or more therapeutic agents.